EFFECT OF TOPICAL BEVACIZUMAB ON RECURRENCE FOLLOWING PTERYGIUM SURGERY WITH CONJUNCTIVAL AUTOGRAFT
Main Article Content
Keywords
Conjunctival autograft, Pterygium, Topical bevacizumab
Abstract
Objectives:
To determine the efficacy of topical bevacizumab in preventing the recurrence in patients undergoing pterygium surgery with conjunctival autograft.
Study Design: Randomized control trial
Place and duration of study: This study was conducted at the AFIO, MH, Rawalpindi, Pakistan from January 2023 to December 2023 over a period of 1 year.
Methods: A total of 80 patients aging between 20-30 years having Pterygium ≥2mm as per diagnosed using slit lamp microscope and decided for surgery were added in the study through consecutive sampling and randomly distributed in to 2 equal groups including a Bevacizumab group and a Control group. All the patients in both groups underwent pterygium excision surgery through conjunctival autograft procedure. In bevacizumab group, patients received topical bevacizumab 5mg/ml administered in the operated eye at 6-hour intervals for the duration of 1 month. No such post-operative treatment was recommended in control group.
The primary outcome was defined as the number of eyes with the recurrence of the pterygium after 3 months of surgery
Results: Mean age of study population was 26.09±2.7 years with age ranging between 20 to 30 years. Out of total patients 56.3% were males while 43.7% were females. Majority of the patients had Type III pterygium (80%) followed by Type II pterygium (20%). The results of study outcomes show that there was no difference between bevacizumab group and control group regarding recurrence of pterygium as per evaluated after 3 month post-operatively (10% Vs 7.5%, respectively, p=0.692).
Conclusion: Topical bevacizumab is not effective in preventing the recurrence in patients undergoing pterygium surgery with conjunctival autograft.
References
2. Rezvan F, Khabazkhoob M, Hooshmand E, Yekta A, Saatchi M, Hashemi H. Prevalence and risk factors of pterygium: a systematic review and meta-analysis. Surv Ophthalmol. 2018;63(5):719-735. doi: 10.1016/j.survophthal.2018.03.001.
3. Kassie Alemayehu T, Addis Y, Yenegeta Bizuneh Z, Mulusew Tegegne M, Alemayehu AM. Prevalence and Associated Factors of Pterygium Among Adults Living in Kolla Diba Town, Northwest Ethiopia. Clin Ophthalmol. 2020;14:245-255. doi: 10.2147/OPTH.S239982.
4. Gupta A, Maurya R P, Manisha, Kadir S M U, Patel A, Devi A, Patel E, et al. Recent update on pterygium. IP Int J Ocul Oncol Oculoplasty. 2022;8(2):95-108.
5. Haq I, Durra M, Tahir M. Prevalence of Pterygium among Welders in Okara District. Ophthalmol Update. 2020;18(2):25-27.
6. Sarkar P, Tripathy K. Pterygium. [Updated 2023 Aug 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558907/.
7. Khan B, Sohail A, Faridi TA, Jan U, Zahid F, Parveen I. Relation between different grades of pterygium and amount of induced corneal astigmatism: Different grades of pterygium. Pak Bio Med J. 2021;4(2):59-63. Available from: https://www.pakistanbmj.com/journal/index.php/pbmj/article/view/74.
8. Akbari M. Update on overview of pterygium and its surgical management. J Popul Ther Clin Pharmacol. 2022;29(4):e30–e45.
9. Palewski M, Budnik A, Konopińska J. Evaluating the Efficacy and Safety of Different Pterygium Surgeries: A Review of the Literature. Int J Environ Res Public Health. 2022;19(18):11357. doi: 10.3390/ijerph191811357.
10. Liu C, Song Y, Wang X, Lai Z, Li C, Wan P, et al. The Key Role of VEGF in the Cross Talk between Pterygium and Dry Eye and Its Clinical Significance. Ophthalmic Res. 2020;63(3):320-331. doi: 10.1159/000503636.
11. Razeghinejad MR, Banifatemi M. Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial. J Ophthalmic Vis Res. 2014;9:22-30
12. Kasetsuwan N, Reinprayoon U, Satitpitakul V. Prevention of Recurrent Pterygium with Topical Bevacizumab 0.05% Eye drops: A Randomized Controlled Trial. Clin Ther.2015;37:2347-51.
13. Fallah Tafti MR, Khosravifard K, Mohammadpour M, Hashemian MN, Kiarudi MY. Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea 2011;30:127-9.
14. Wu PC, Kuo HK, Tai MH, Shin SJ. Topical bevacizumab eyedrops for limbal- conjunctival neovascularizationin impending recurrent pterygium. Cornea. 2009;28(1):103–4.
15. Dar MY, Bhat MZ. The Outcome of Preoperative Subconjunctival Bevacizumab Injection In Pterygium Surgery. Int J Curr Adv Res. 2022;11(06):1123-6. DOI: http://dx.doi.org/10.24327/ijcar.2022. 1126.0251.
16. Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 2010;35:17-22.
17. Hwang S, Choi S. A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery. Korean J Ophthalmol. 2015 Dec;29(6):375-81. doi: 10.3341/kjo.2015.29.6.375.
18. Motarjemizadeh Q, Aidenloo NS and Sepehri S. A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study. Int Ophthalmol. 2016;36:63–71.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Muhammad Khizar Niazi
FCPS (Ophthalmology), FCPS (Vitreo-Retina), FRCS Glasg (Ophthalmology), Medical Retina Fellowship (Birmingham, UK), Professor of Ophthalmology, CIMS Medical College Multan, NUMS, Pakistan
Dr. Kashif Ali
MBBS, FCPS, CHPE, Associate Professor, CIMS Multan, NUMS, Pakistan
Dr. Saad Mushtaq Malik
MBBS, FCPS (Ophthalmology), CHPE (NUMS), Consultant Ophthalmologist & Assistant Professor of Ophthalmology, CIMS Medical College, Multan
Dr. Farooq Ahmed
MBBS, FCPS, Senior Registrar CIMS Multan, NUMS Pakistan
Dr. Hifza Masood
MBBS, FCPS, Registrar Ophthalmology, CMH and CIMS Multan
Dr. Ifrah Idrees Lodhi
MBBS, FCPS(I), Resident CMH Multan